Who are Vaginal estradiol tablets's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): estradiol valerat, Estradiol 0.01% Vag Cream, Estriol Cream 0.1%, estriol cream, Generic Estradiol Vaginal Cream USP, 0.01%, estradiol (Zesteem).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/vaginal-estradiol-tablets.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Vaginal estradiol tablets — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Vaginal estradiol tablets (Vaginal estradiol tablets) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Estrogen receptor agonist. Area: Women's Health / Gynecology.

marketed Estrogen receptor agonist Estrogen receptor alpha (ERα) and estrogen receptor beta (ERβ) Women's Health / Gynecology Small molecule Live · refreshed every 30 min

Target snapshot

Vaginal estradiol tablets (Vaginal estradiol tablets) — Johns Hopkins University. Vaginal estradiol tablets deliver estrogen directly to vaginal tissue to relieve symptoms of vaginal atrophy and genitourinary syndrome of menopause.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Vaginal estradiol tablets TARGET	Vaginal estradiol tablets	Johns Hopkins University	marketed	Estrogen receptor agonist	Estrogen receptor alpha (ERα) and estrogen receptor beta (ERβ)
estradiol valerat	estradiol valerat	farzaneh hojjat	marketed	Estrogen receptor agonist	Estrogen receptor alpha (ERα), Estrogen receptor beta (ERβ)
Estradiol 0.01% Vag Cream	Estradiol 0.01% Vag Cream	TriHealth Inc.	marketed	Estrogen receptor agonist	Estrogen receptor alpha (ERα) and estrogen receptor beta (ERβ)
Estriol Cream 0.1%	Estriol Cream 0.1%	Dr. August Wolff GmbH & Co. KG Arzneimittel	marketed	Estrogen receptor agonist	Estrogen receptor alpha (ERα) and estrogen receptor beta (ERβ)
estriol cream	estriol cream	Hatice Tukenmez Kurnaz	marketed	Estrogen receptor agonist	Estrogen receptor alpha (ERα) and estrogen receptor beta (ERβ)
Generic Estradiol Vaginal Cream USP, 0.01%	Generic Estradiol Vaginal Cream USP, 0.01%	Actavis Inc.	phase 3	Estrogen receptor agonist	Estrogen receptor alpha (ERα), Estrogen receptor beta (ERβ)
estradiol (Zesteem)	estradiol (Zesteem)	Renovo	phase 3	estrogen receptor agonist	estrogen receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Estrogen receptor agonist class)

Actavis Inc. · 1 drug in this class
Bayer · 1 drug in this class
Dr. August Wolff GmbH & Co. KG Arzneimittel · 1 drug in this class
Hatice Tukenmez Kurnaz · 1 drug in this class
Johns Hopkins University · 1 drug in this class
Martin Blomberg Jensen · 1 drug in this class
TriHealth Inc. · 1 drug in this class
farzaneh hojjat · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Vaginal estradiol tablets — Competitive Intelligence Brief. https://druglandscape.com/ci/vaginal-estradiol-tablets. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing